Evidence map›Paper›PMID 21079516›Full record

ArticleJournal of acquired immune deficiency syndromes (1999)2011

CD8 T-cell proliferative capacity is compromised in primary HIV-1 infection.

Sonya L Heath, Steffanie Sabbaj, Anju Bansal, J Michael Kilby, Paul A Goepfert

Abstract read
In one paragraph

Article in Journal of acquired immune deficiency syndromes (1999), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Gene array studies in HIV-1 infection.Current HIV/AIDS reports · 2012
    Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Sonya L HeathDepartment of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA. heaths@uab.edu
Steffanie Sabbaj
Anju Bansal
J Michael Kilby
Paul A Goepfert

Funding

Virology CoreP30AI027767 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Paul A. Goepfert · 1988 to 2026
$84.1M
Zevalin Radioimmunotherapy Using a Modified TreatmentM01RR000032 · NCRR · UNIVERSITY OF SOUTHERN CALIFORNIA · PI RICH, ROBERT R. · 1985 to 2008
$23.6M
UAB CENTER FOR CLINICAL AND TRANSLATIONAL SCIENCE (CCTS) UL1: BPCAUL1RR025777 · NCRR · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI KIMBERLY, ROBERT P. · 2008 to 2011
$22.3M
CTL and HIV Polymorphisms in Heterosexual TransmissionR01AI064060 · NIAID · EMORY UNIVERSITY · PI GOEPFERT, PAUL A., HUNTER, ERIC · 2005 to 2019
$21.7M
HIV-1 Cryptic Epitopes: Implications for Vaccine DesignR01AI084772 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI GOEPFERT, PAUL A. · 2009 to 2013
$2.5M
Professional Skills for Minority Students in BiomedicineT36GM073062 · NIGMS · AMERICAN PHYSIOLOGICAL SOCIETY · PI MATYAS, MARSHA LAKES · 2005 to 2007
$977k
Survival Factors Regulating the HIV-Specific Cytotoxic T Lymphocyte ResponseK08AI076056 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI HEATH, SONYA L · 2007 to 2011
$678k
HIV-1 Suppression by MHC class I restricted CD8 T CellsR21AI073103 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI GOEPFERT, PAUL A. · 2007 to 2008
$395k
NCRR NIH HHS 5UL1 RR025777-03NCRR NIH HHS M01 RR000032NCRR NIH HHS M0-RR00032NCRR NIH HHS UL1 RR025777NIAID NIH HHS K08 AI076056NIAID NIH HHS L30 AI066715NIAID NIH HHS P30 AI027767NIAID NIH HHS P30AI027767NIAID NIH HHS P30 AI27767NIAID NIH HHS R01 AI064060NIAID NIH HHS R01 AI084772NIAID NIH HHS R21 AI073103NIAID NIH HHS R21 AI73103NIGMS NIH HHS 5T36GM73062NIGMS NIH HHS T36 GM073062PHS HHS U01 A101008
6 · The paper itself

Abstract

Understanding the correlates of immunity that control HIV-1 infection is imperative to our understanding of HIV-1 disease and vaccine development. HIV-1-specific cytotoxic T lymphocytes are fundamental to the control of viremia; however, which T-cell repertoire components enact this control remains unclear. We hypothesize that polyfunctional HIV-1-specific CD8 T cells capable of viral control are present in most patients early in infection and these cells are distinguished by their ability to secrete interleukin (IL)-2 and proliferate. We examined HIV-1-specific CD8 T-cell proliferation and cytokine secretion in primary HIV-1 infection (PHI) using known HIV-1 cytotoxic T-cell epitopes to exclude CD4 bystander effect. We found that only a subset of patients with PHI demonstrated "CD4-independent" CD8 proliferation ex vivo. The remainder of the patients lacked HIV-1-specific CD8 T cells with proliferative capacity, even after the addition of exogenous IL-2. Among the proliferators, IL-2 production from the total HIV-specific CD8 T-cell population correlated with proliferation. Surprisingly, though, we did not routinely detect both IL-2 secretion and proliferative capacity from the same antigen-specific CD8 T cells. Thus, there are distinct and heterogeneous populations of CD8 T cells, phenotypically characterized by either proliferation or IL-2 secretion and few with dual capacity. Generation of these responses may be an important measure of HIV-1 control but are not universal after PHI. Furthermore, the heterogeneity of this population suggests that a simple measure of an effective vaccine response remains elusive.

Indexed as

CD8-Positive T-LymphocytesCell ProliferationHIV-1HIV InfectionsHumansInterleukin-2Lymphocyte SubsetsInterleukin-2

Identifiers

PMID21079516
PMCPMC3832295

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.